RE
CBMG

RBC Europe’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

RBC Europe’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-725
Closed -$7.72K – 1165
2017
Q3 		$7.72K Buy
+725
New +$6.86K ﹤0.01% 892

Other funds holding CBMG

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RBC Europe's CBMG Position: Q4 2017 in Review

RBC Europe sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2017, closing a stake of 725 shares — an estimated $7.72K sold.

RBC Europe first reported a position in CBMG in Q3 2017 and held it in 1 quarter. The position peaked at $7.72K in Q3 2017. 17 funds tracked by Wall St. Rank hold CBMG as of Q4 2017.

  • RBC Europe reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2017 after selling out during the quarter.
  • RBC Europe sold 725 Cellular Biomedicine Group, Inc. shares in Q4 2017, an estimated $7.72K.
  • RBC Europe first reported a position in Cellular Biomedicine Group, Inc. in Q3 2017 and held it in 1 quarter.
  • RBC Europe's Cellular Biomedicine Group, Inc. position peaked at $7.72K in Q3 2017.
  • 17 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.